Connect with us

Tools & Platforms

What is Mistral AI? Everything to know about the OpenAI competitor

Published

on


Mistral AI, the French company behind AI assistant Le Chat and several foundational models, is officially regarded as one of France’s most promising tech startups and is arguably the only European company that could compete with OpenAI.

It is reportedly in the process of raising another round that would value it at $14 billion, up from about $6 billion in June, 2024. While Mistral AI describes itself as “the world’s greenest and leading independent AI lab” it is still not as well known as its biggest competitors.  

“Go and download Le Chat, which is made by Mistral, rather than ChatGPT by OpenAI — or something else,” French president Emmanuel Macron said in a TV interview ahead of the AI Action Summit in Paris in February 2025.

What is Mistral AI?

Mistral AI, which offers open-source AI models, has raised significant amounts of funding since its creation in 2023 with the ambition to “put frontier AI in the hands of everyone.” While this isn’t a direct jab at OpenAI, the slogan is meant to highlight the company’s openness versus OpenAI’s typically closed approach.

Its alternative to ChatGPT, chat assistant Le Chat, is available on iOS and Android. It reached 1 million downloads in the two weeks following its mobile release, even grabbing France’s top spot for free downloads on the iOS App Store.

In July 2025, Mistral AI updated Le Chat with new features that bring it closer to rival full-stack AI chatbots: a new “deep research” mode, native multilingual reasoning, and advanced image editing. This update also includes the addition of Projects, which lets users group chats, documents, and ideas into focused spaces.

As of September 2025, Le Chat also has the ability to remember previous conversations with the introduction of Memories.

Techcrunch event

San Francisco
|
October 27-29, 2025

This comes in addition to Mistral AI’s suite of models, which includes: 

In March 2025, the company introduced Mistral OCR, an optical character recognition (OCR) API that can turn any PDF into a text file to make it easier for AI models to ingest.

In June 2025, Mistral AI also released a vibe coding client, Mistral Code, to compete with incumbents like Windsurf, Anysphere’s Cursor, and GitHub Copilot.

Who are Mistral AI’s founders?

Mistral AI’s three founders share a background in AI research at major U.S. tech companies with significant operations in Paris. CEO Arthur Mensch used to work at Google’s DeepMind, while CTO Timothée Lacroix and chief scientist officer Guillaume Lample are former Meta staffers.

Co-founding advisers also include Jean-Charles Samuelian-Werve (also a board member) and Charles Gorintin from health insurance startup Alan, as well as former digital minister Cédric O, which has caused persistent controversy due to his previous role.

Are Mistral AI’s models open source?

Not all of them. Mistral AI differentiates its premier models, whose weights are not available for commercial purposes, from its free models, for which it provides weight access under the Apache 2.0 license.

Free models include research models such as Mistral NeMo, which was built in collaboration with Nvidia that the startup open sourced in July 2024.

How does Mistral AI make money?

While many of Mistral AI’s offerings are free or now have free tiers, Le Chat also has paid tiers. Introduced in February 2025, Le Chat’s Pro plan is priced at $14.99 a month.

On the purely B2B side, Mistral AI monetizes its premier models through APIs with usage-based pricing. Enterprises can also license these models, and the company likely also generates a significant share of its revenue from its strategic partnerships, some of which it highlighted during the Paris AI Summit.

Overall, however, Mistral AI’s revenue is reportedly still in the eight-digit range, according to multiple sources.

What partnerships has Mistral AI closed?

In 2024, Mistral AI entered a deal with Microsoft that included a strategic partnership for distributing its AI models through Microsoft’s Azure platform and a €15 million investment. The U.K.’s Competition and Markets Authority (CMA) swiftly concluded that the deal didn’t qualify for investigation due to its small size. However, it also sparked some criticism in the EU. 

In January 2025, Mistral AI signed a deal with press agency Agence France-Presse (AFP) to let Chat query the AFP’s entire text archive dating back to 1983.

Mistral AI also secured strategic partnerships with France’s army and job agency, Luxembourg, shipping giant CMA, German defense tech startup Helsing, IBM, Orange, and Stellantis.

In May 2025, Mistral AI announced it would participate in the creation of an AI Campus in the Paris region, as part of a joint venture with UAE-investment firm MGX, NVIDIA, and France’s state-owned investment bank Bpifrance.

In June 2025, it was announced that beginning in 2026, Mistral will launch a European platform dedicated to AI and powered by Nvidia processors, Mistral Compute. The initative was hailed as ‘historic’ by Macron, who shared the stage with Mensch and Nvidia CEO Jensen Huang at the VivaTech conference shortly after the announcement.

In July 2025, it announced AI for Citizens, “a collaborative initiative to help States and public institutions strategically harness AI for their people by transforming public services, catalyzing innovation, and ensuring competitiveness.”

What enterprise features has Mistral AI developed?

In May 2025, Mistral AI released the Mistral Agents API to “empower enterprises to use AI in more practical and impactful ways,” according to its Head of Developer Relations, Sophia Yang.

In September 2025, the company unveiled a revamped Connectors directory, showcasing Le Chat’s integrations with some 20 enterprise tools including Asana, Atlassian, Box, Google Drive, Notion, Zapier, as well as emails and calendars; and soon, Databricks and Snowflake.

How much funding has Mistral AI raised to date?

As of February 2025, Mistral AI raised around €1 billion in capital to date, approximately $1.04 billion at the current exchange rate. This includes some debt financing, as well as several equity financing rounds raised in close succession.

In June 2023, and before it even released its first models, Mistral AI raised a record $112 million seed round led by Lightspeed Venture Partners. Sources at the time said the seed round — Europe’s largest ever — valued the then-one-month-old startup at $260 million. 

Other investors in this seed round included Bpifrance, Eric Schmidt, Exor Ventures, First Minute Capital, Headline, JCDecaux Holding, La Famiglia, LocalGlobe, Motier Ventures, Rodolphe Saadé, Sofina, and Xavier Niel.

Only six months later, it closed a Series A of €385 million ($415 million at the time), at a reported valuation of $2 billion. The round was led by Andreessen Horowitz (a16z), with participation from existing backer Lightspeed, as well as BNP Paribas, CMA-CGM, Conviction, Elad Gil, General Catalyst, and Salesforce.

The $16.3 million convertible investment that Microsoft made in Mistral AI as part of their partnership announced in February 2024 was presented as a Series A extension, implying an unchanged valuation.

In June 2024, Mistral AI then raised €600 million in a mix of equity and debt (around $640 million at the exchange rate at the time). The long-rumored round was led by General Catalyst at a $6 billion valuation, with notable investors, including Cisco, IBM, Nvidia, Samsung Venture Investment Corporation, and others.

According to Bloomberg, Mistral AI is now finalizing a €2 billion investment at a post-money valuation of $14 billion. This follows earlier reports that the company was in talks to raise $1 billion in equity from investors including Abu Dhabi’s MGX fund, as well as hundreds of millions of euros in debt. But

How is Mistral AI approaching AI regulation?

Mensch was part of a group of European CEOs who signed an open letter in July 2025 urging Brussels to ‘stop the clock’ for two years before key obligations of the EU Artificial Intelligence Act enter into force. The European Commision is sticking to its original timeline.

What could a Mistral AI exit look like?

Mistral is “not for sale,” Mensch said in January 2025 at the World Economic Forum in Davos. “Of course, [an IPO is] the plan.” 

This makes sense, given how much the startup has raised so far: Even a large sale may not provide high enough multiples for its investors, not to mention sovereignty concerns depending on the acquirer. 

However, the only way to definitely squash persistent acquisition rumors — lately naming Apple — is to scale its revenue to levels that could even remotely justify its valuation. Either way, stay tuned.

This story was originally published on February 28, 2025 and will be regularly updated.



Source link

Tools & Platforms

DeepMind CEO Demis Hassabis: ‘AI could cut drug discovery from years to…’; how it is changing medicine worldwide |

Published

on


Artificial intelligence (AI) is rapidly transforming industries, and the pharmaceutical sector is poised to be one of its most significant beneficiaries, reshaping how drugs are discovered, tested, and brought to market. In a recent Bloomberg Television interview, Demis Hassabis, CEO of DeepMind and Nobel laureate, revealed that AI could dramatically reduce drug discovery timelines, potentially cutting years of labor-intensive research down to mere months. DeepMind’s advanced AI models aim to streamline the identification of promising drug candidates, enhance precision, optimize molecular design, and reduce the high failure rates that have historically plagued pharmaceutical development. This breakthrough promises faster access to innovative treatments, lower development costs, improved patient outcomes, and a transformative new era of medical research powered by sophisticated computational intelligence and predictive modeling.

How AI is changing the drug discovery process: DeepMind CEO reveals

Traditional drug discovery involves painstaking laboratory experiments, lengthy clinical trials, and significant trial-and-error testing, often taking 10–15 years from concept to market. According to Hassabis, AI can radically alter this timeline.“In the next couple of years, I’d like to see that cut down in a matter of months, instead of years,” Demis Hassabis said in an interview with Bloomberg Television. “That’s what I think is possible. Perhaps even faster.”DeepMind’s subsidiary, Isomorphic Labs, leverages AI to model complex biological systems, analyse molecular structures, and predict interactions between drugs and proteins. In the Bloomberg interview, Hassabis highlighted that AI can process enormous datasets far faster than human researchers, enabling the identification of promising drug candidates within weeks instead of years.This accelerated approach could not only save valuable time but also optimize resource allocation, ensuring that researchers focus on molecules with the highest likelihood of success.

How AI predictive models are transforming drug discovery and minimising setbacks

A major challenge in drug discovery is the high failure rate: many compounds that look promising in early tests fail in later stages due to inefficacy or harmful side effects. Hassabis emphasized that AI’s predictive capabilities could reduce these failures significantly.DeepMind’s models simulate protein folding and chemical interactions, allowing scientists to forecast how molecules behave in the body. The AI can also suggest novel molecular structures that traditional methods might overlook, expanding the pool of potential therapeutics. By prioritizing candidates most likely to succeed, AI improves efficiency and reduces costly setbacks in research.

AI’s role in speeding up drug development and expanding access

Hassabis discussed the broader implications of AI-driven drug discovery in the Bloomberg interview. Faster development cycles could allow for quicker responses to pandemics, emerging diseases, and critical health crises. Moreover, AI could facilitate the creation of personalized medicine, tailoring treatments to individual genetic profiles, metabolic rates, and disease characteristics.Beyond speed, AI’s efficiency could lower drug development costs, making treatments more accessible globally. This democratization of medicine could have profound social impacts, particularly for developing nations where access to cutting-edge therapies is limited.

From Alzheimer’s to rare cancers: AI leads the way

While Hassabis did not provide specific drug names in the interview, he emphasized that AI models are already being applied to several disease areas, including neurodegenerative disorders, rare genetic conditions, and chronic illnesses. Early studies suggest that computational predictions could significantly reduce the experimental burden and provide actionable leads for human trials.For instance, modeling protein-drug interactions can identify compounds that might mitigate protein misfolding in diseases such as Alzheimer’s. Similarly, AI-driven analysis of molecular pathways could accelerate treatments for rare cancers where conventional drug development is often economically unviable.

AI-driven drug discovery: Challenges

Despite its promise, AI-driven drug discovery is not without challenges. Hassabis pointed out several critical considerations:

  • Regulatory oversight: AI-generated predictions must undergo rigorous validation to meet global drug approval standards.
  • Ethical concerns: Ensuring AI recommendations are safe and equitable is vital, particularly when designing personalized therapies.
  • Collaboration needs: Successful implementation requires coordination between AI specialists, molecular biologists, pharmacologists, and clinicians.

Addressing these challenges will be crucial to translating AI’s predictive power into real-world therapies.Also Read | Abidur Chowdhury: Meet the designer behind Apple’s ultra-slim iPhone Air and its futuristic technology





Source link

Continue Reading

Tools & Platforms

Apple’s AI and search executive Robby Walker to leave: Report

Published

on


FILE PHOTO: Robby Walker, one of Apple’s most senior AI executives, is leaving the company.
| Photo Credit: AP

Robby Walker, one of Apple’s most senior artificial intelligence executives, is leaving the company, Bloomberg News reported on Friday, citing people with knowledge of the matter.

Walker’s exit comes as Apple’s cautious approach to AI has fueled concerns it is sitting out what could be the industry’s biggest growth wave in decades.

The company was slow to roll out its Apple Intelligence suite, including a ChatGPT integration, while a long-awaited AI upgrade to Siri has been delayed until next year.

Walker has been the senior director of the iPhone maker’s Answers, Information and Knowledge team since April this year. He has been with Apple since 2013, according to his LinkedIn profile.

He is planning to leave Apple next month, the report said. Walker was in charge of Siri until earlier this year, before management of the voice assistant was shifted to software chief Craig Federighi.

Apple did not immediately respond to a Reuters request for comment.

Recently, Apple has seen a slew of its AI executives leave to join Meta Platforms. The list includes Ruoming Pang, Apple’s top executive in charge of AI models, according to a Bloomberg report from July.

Meta has also hired two other Apple AI researchers, Mark Lee and Tom Gunter — who worked closely with Pang — for its Superintelligence Labs team.

Mike Rockwell, vice president in charge of the Vision Products Group, would be in charge of Siri virtual assistant as CEO Tim Cook has lost confidence in AI head John Giannandrea’s ability to execute on product development, Bloomberg had reported in March.

At its annual product launch event last week, Apple introduced an upgraded line of iPhones, alongside a slimmer iPhone Air, and held prices steady amid U.S. President Donald Trump’s tariffs that have hurt the company’s profit.

The event, though, was light on evidence of how Apple — a laggard in the AI race — aimes to close the gap with the likes of Google, which showcased the capabilities of its Gemini AI model in its latest flagship phones.



Source link

Continue Reading

Tools & Platforms

Nano Banana AI: ChatGPT vs Qwen vs Grok vs Gemini; the top alternatives to try in 2025 – The Times of India

Published

on



Nano Banana AI: ChatGPT vs Qwen vs Grok vs Gemini; the top alternatives to try in 2025  The Times of India



Source link

Continue Reading

Trending